JP Morgan: Witty Happy To Be 'Promiscuous' To Rebuild GSK's Oncology Presence
This article was originally published in Scrip
Andrew Witty has taken a lot of flak over the past couple of years as GlaxoSmithKline Plc. lurched from one 'challenge' to another – from the bribery scandal in China and corruption allegations elsewhere, to a string of late-stage product failures, to a less than stellar uptake of its new respiratory franchise. But things are now on a steady footing and the UK-based pharma major is entering a growth phase, if the CEO's comments at the 34th annual JP Morgan Healthcare Conference on Jan. 13 are to betaken at face value.
You may also be interested in...
The company showed signs of stabilization in the first quarter, as Witty insisted his diversified strategy is beginning to pay off. But a new CEO will have to contend with the potential entry of Advair generics.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.